Cost Of Providing CAR-T Therapies Could Derail Reimbursement In England
Gilead claims that the mechanism used to work out the cost for the National Health Service in England of delivering CAR-T therapies to patients could threaten access to these medicines.
You may also be interested in...
Two oncology chiefs from the French firm talked to Scrip about how its pipeline echoes the emerging intersection between precision medicine and immuno-oncology and how biology is taking precedence over technology in cancer R&D.
The ABPI, which represents the R&D-based pharmaceutical industry in the UK, says the proposed increase in the statutory scheme rebate sends "the worst possible signal" to global investors and boardrooms.
The German pharmaceutical industry is calling for “directional correction” to the way implementation of the EU’s Health Technology Assessment Regulation is being developed.